Physician profile
John Mark Flack
NPI 1164450987
$157,770.85
in general payments reported to CMS, 2019-2025
14 companies · $26K in 2025
The $26K reported for 2025 was more than what 78% of Hypertension Specialist providers received nationally (typical 2025 total: $1,007).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,744 · 2021: $2,250 · 2022: $28K · 2023: $16K · 2024: $76K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $89K · Travel and Lodging: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,520 · Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $88,650.46 |
| Travel and Lodging | $24,575.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,520.00 |
| Food and Beverage | $2,345.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $95,860.72 | 2023-2025 | |
| Ardelyx, INC. | $11,050.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $9,744.28 | 2019 | |
| Ipsen Bioscience INC. | $9,690.00 | 2022 | |
| Glaxosmithkline, LLC. | $9,600.00 | 2023 | |
| Azurity Pharmaceuticals, INC. | $8,416.35 | 2025 | Widaplik |
| Janssen Pharmaceuticals, INC | $5,048.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $2,572.28 | 2024-2025 | Tryvio |
| Amgen INC. | $2,250.00 | 2021 | |
| Janssen Global Services, LLC | $1,800.00 | 2022 | |
| Recor Medical INC | $1,641.57 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Janssen Scientific Affairs, LLC | $96.85 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Flack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.